Clinical Trial Update: Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating cytokine levels, gene expression, and safety after a single nasal dose of JNJ-43260295 in healthy participants and individuals with mil…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• JNJ-43260295

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Healthy, Asthma | Phase 1 | Status: TERMINATED